Prohibitin, a potential tumor suppressor, interacts with rb and regulates e2f function


Prohibitin, a potential tumor suppressor, interacts with rb and regulates e2f function

Play all audios:


ABSTRACT The retinoblastoma tumor suppressor protein and its family members, p107 and p130, are major regulators of the mammalian cell cycle. They exert their growth suppressive effects at


least in part by binding the E2F family of transcription factors and inhibiting their transcriptional activity. Agents that disrupt the interaction between Rb family proteins and E2F promote


cell proliferation. Here we describe the characterization of a novel interaction between Rb family proteins and a potential tumor suppressor protein, prohibitin. Prohibitin physically


interacts with all three Rb family proteins _IN VITRO_ and _IN VIVO_, and was very effective in repressing E2F-mediated transcription. Prohibitin could inhibit the activity of E2Fs 1, 2, 3,


4 and 5, but could not affect the activity of promoters lacking an E2F site. Surprisingly, prohibitin-mediated repression of E2F could not be reversed by adenovirus E1A protein. A prohibitin


mutant that could not bind to Rb was impaired in its ability to repress E2F activity and inhibit cell proliferation. We believe that prohibitin is a novel regulator of E2F activity that


responds to specific signaling cascades. Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through


your institution Subscribe to this journal Receive 50 print issues and online access $259.00 per year only $5.18 per issue Learn more Buy this article * Purchase on SpringerLink * Instant


access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions *


Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS CELL CYCLE REGULATION: P53-P21-RB SIGNALING Article Open access 31 March 2022 AN INTERMEDIATE RB–E2F ACTIVITY


STATE SAFEGUARDS PROLIFERATION COMMITMENT Article Open access 26 June 2024 HDAC ACTIVITY IS DISPENSABLE FOR REPRESSION OF CELL-CYCLE GENES BY DREAM AND E2F:RB COMPLEXES Article Open access


24 May 2024 REFERENCES * Adams PD and Kaelin WJ. . 1996a _Semin. Cancer Biol._ 6: 99–108. * Adams PD and Kaelin WJ. . 1996b _Curr. Top. Microbiol. Immunol._ 208: 79–93. * Bagchi S, Weinmann


R and Raychaudhuri P. . 1991 _Cell_ 65: 1073–1082. * Bandara LR, Lam EW, Sorensen TS, Zamanian M, Girling R and La TN. . 1994 _EMBO J._ 13: 3104–3114. * Beijersbergen RL and Bernards R. .


1996 _Biochim. Biophys. Acta_ 1287: 103–120. * Beijersbergen RL, Carlee L, Kerkhoven RM and Bernards R. . 1995 _Genes Dev._ 9: 1340–1353. * Beijersbergen RL, Kerkhoven RM, Zhu L, Carlee L,


Voorhoeve PM and Bernards R. . 1994 _Genes & Development_ 8: 2680–2690. * Bishop JM. . 1991 _Cell_ 64: 235–248. * Brehm A, Miska EA, McCance DJ, Reid JL, Bannister AJ and Kouzarides T. .


1998 _Nature_ 391: 597–601. * Chellappan SP. . 1994 _Mol. Cell. Diff._ 2: 201–220. * Chellappan SP, Hiebert S, Mudryj M, Horowitz JM and Nevins JR. . 1991 _Cell_ 65: 1053–1061. * Chellappan


S, Kraus VB, Kroger B, Munger K, Howley PM, Phelps WC and Nevins JR. . 1992 _Proc. Natl. Acad. Sci. USA_ 89: 4549–4553. * Claudio PP, De LA, Howard CM, Baldi A, Firpo EJ, Koff A, Paggi MG


and Giordano A. . 1996 _Cancer Res._ 56: 2003–2008. * Claudio PP, Howard CM, Baldi A, De LA, Fu Y, Condorelli G, Sun Y, Colburn N, Calabretta B and Giordano A. . 1994 _Cancer Res._ 54:


5556–5560. * Cobrinik D. . 1996 _Curr. Top. Micro. Immunol._ 208: 32–63. * Cobrinik D, Whyte P, Peeper DS, Jacks T and Weinberg RA. . 1993 _Genes & Dev._ 7: 2392–2404. * Corbeil HB,


Whyte P and Branton PE. . 1995 _Oncogene_ 11: 909–920. * Cox LA, Chen G and Lee EY. . 1994 _Breast Cancer Res. Treat._ 32: 19–38. * Cropp CS. . 1995 _Cancer Lett._ 90: 51–56. * Duronio RJ,


Bonnette PC and O'Farrell PH. . 1998 _Mol. Cell. Biol._ 18: 141–151. * Dyson N. . 1994 _J. Cell. Sci. Suppl._ 18: 81–87. * Ewen ME. . 1994 _Cancer Metast. Rev._ 13: 45–66. * Ewen ME,


Faha B, Harlow E and Livingston DM. . 1992 _Science_ 255: 85–87. * Ewen ME, Sluss HK, Sherr CJ, Matsushime H, Kato J and Livingston DM. . 1993 _Cell_ 73: 489–497. * Faha B, Ewen ME, Tsai LH,


Livingston DM and Harlow E. . 1992 _Science_ 255: 87–90. * Franklin DS and Jazwinski SM. . 1993 _J. Cell. Biochem. Suppl._ 17D: 159. * Grana X and Reddy EP. . 1995 _Oncogene_ 11: 211–219. *


Hamel PA and Hanley-Hyde J. . 1997 _Cancer Invest._ 15: 143–152. * Hauser PJ, Agrawal D, Chu B and Pledger WJ. . 1997 _J. Biol. Chem._ 272: 22954–22959. * Helin K, Lees JA, Vidal M, Dyson


N, Harlow E and Fattaey A. . 1992 _Cell_ 70: 337–350. * Hiebert SW, Chellappan SP, Horowitz JM and Nevins JR. . 1992 _Genes Dev._ 6: 177–185. * Ikeda MA, Jakoi L and Nevins JR. . 1996 _Proc.


Natl. Acad. Sci. USA_ 93: 3215–3220. * Jiang H, Lin J, Young S, Goldstein NI, Waxman S, Davila V, Chellappan SP and Fisher PB. . 1995 _Oncogene_ 11: (in press). * Johnson DG, Schwarz JK,


Cress WD and Nevins JR. . 1993 _Nature_ 365: 349–352. * Junaief JL, Strober BE, Guha S, Khavari PA, Alin K, Luban J, Begenman M and Goff SP. . 1994 _Cell_ 79: 119–130. * Kaelin WG, Krek W,


Sellers WR, DeCaprio JA, Ajchenbaum F, Fuchs CS, Chittenden T, Li Y, Farnham PJ, Blanar MA, Livingstone DM and Flemington EK. . 1992 _Cell_ 70: 351–364. * Kamb A. . 1995 _Trends Genet._ 11:


136–140. * Kato J, Matsushime H, Hiebert SW, Ewen ME and Sherr CJ. . 1993 _Genes Dev._ 7: 331–342. * Kohn KW. . 1998 _Oncogene_ 16: 1065–1075. * La Thangue NB. . 1994 _Trends Biochem. Sci._


19: 108–114. * La Thangue NB. . 1996 _Biochem. Soc. Trans._ 24: 54–59. * Lam EW, Choi MS, van der Sman J, Burbidge SA and Klaus GG. . 1998 _J. Biol. Chem._ 273: 10051–10057. * Lam EW and La


Thangue NB. . 1994 _Curr. Opin. Cell. Biol._ 6: 859–866. * Lee EY, To H, Shew JY, Bookstein R, Scully R and Lee WH. . 1988 _Science_ 241: 218–221. * Lees E, Faha B, Dulic V, Reed SI and


Harlow E. . 1992 _Genes Dev._ 6: 1874–1885. * Liu XT, Stewart CA, King RL, Danner DAn Dell'Orco RT and McClung JK. . 1994 _Biochem. Biophys. Res. Comm._ 201: 409–414. * Lundberg AS and


Weinberg RA. . 1998 _Mol. Cell. Biol._ 18: 753–761. * Luo RX, Postigo AA and Dean DC. . 1998 _Cell_ 92: 463–473. * MacLachlan TK, Sang N and Giordano A. . 1995 _Crtic. Rev. Eukaryot. Gene


Exp._ 5: 127–156. * Magnaghi-Jaulin L, Groisman R, Naguibneva I, Robin P, Lorain S, Le Villain JP, Troalen F, Trouche D and Harel-Bellan A. . 1998 _Nature_ 391: 601–605. * Marshall CJ. .


1991 _Cell_ 64: 313–326. * McClung JK, Danner DB, Stewart DA, Smith JR, Schneider EL, Lumpkin CK, Dell'Orco RT and Nuell MJ. . 1989 _Biochem. Biophys. Res. Comm._ 164: 1316–1322. *


McClung JK, Jupe ER, Liu X-T and Dell'Orco RT. . 1995 _Exper. Gerontol._ 30: 99–124. * Meyerson M, Enders GH, Wu CL, Su LK, Gorka C and Nelson C. . 1992 _Genes Dev._ 6: 1874–1885. *


Nevins JR. . 1992 _Science_ 258: 424–429. * Nevins JR. . 1993 _Biochem. Soc. Tran._ 21: 935–938. * Nevins JR. . 1994 _Curr. Opin. Gen. Dev._ 4: 130–134. * Nuell MJ, Stewart DA, Walker L,


Friedman V, Wood CM, Owens GA, Smith JR, Schneider EL, Dell' OR, Lumpkin CK, Danner DB and McClung JK. . 1991 _Mol. Cell. Biol._ 11: 1372–1381. * Pines J. . 1995 _Semin. Cancer. Biol._


308: 697–711. * Qin XQ, Livingston DM, Ewen M, Sellers WR, Arany Z and Kaelin WJ. . 1995 _Mol. Cell. Biol._ 15: 742–755. * Roskams AJ, Friedman V, Wood CM, Walker L, Owens GA, Stewart DA,


Altus MS, Danner DB, Liu XT and McClung JK. . 1993 _J. Cell. Phys._ 157: 289–295. * Sato T, Saito H, Swensen J, Olifant A, Wood C, Danner D, Sakamoto T, Takita K, Kasumi F, Miki Y, Skolnick


M and Nakamura Y. . 1992 _Cancer Res._ 52: 1643–1646. * Sato T, Sakamoto T, Takita K, Saito H, Okui K and Nakamura Y. . 1993 _Genomics_ 17: 762–764. * Sherr CJ. . 1994 _Trends. Cell. Biol._


4: 15–18. * Sherr CJ and Roberts JM. . 1995 _Genes Dev._ 9: 1149–1163. * Shirodkar S, Ewen M, DeCaprio JA, Morgan J, Livingston DM and Chittenden T. . 1992 _Cell_ 68: 157–166. * Slansky JE


and Farnham PJ. . 1996 _Curr. Top. Microbiol. Immunol._ 208: 1–30. * Strom DK, Cleveland JL, Chellappan S, Nip J and Hiebert SW. . 1998 _Cell Growth Differ._ 9: 59–69. * Sutherland RL,


Hamilton JA, Sweeney KJ, Watts CK and Musgrove EA. . 1995 _Acta Oncol._ 34: 651–656. * Taya Y. . 1997 _Trends Biochem. Sci._ 22: 14–17. * Terashima M, Kim KM, Adachi T, Nielsen PJ, Reth M,


Kohler G and Lamers MC. . 1994 _EMBO J._ 13: 3782–3792. * Tordai A, Franklin RA, Patel H, Gardner AM, Johnson GL and Gelfand EW. . 1994 _J. Biol. Chem._ 269: 7538–7543. * Trimarchi JM,


Fairchild B, Verona R, Moberg K, Andon N and Lees JA. . 1998 _Proc. Natl. Acad. Sci. USA_ 95: 2850–2855. * Trouche D, Cook A and Kouzarides T. . 1996 _Nucl. Acid Res._ 24: 4139–4145. *


Trouche D and Kouzarides T. . 1996 _Proc. Natl. Acad. Sci. USA_ 93: 1439–1442. * Vojtek AB, Hollenberg SM and Cooper JA. . 1993 _Cell_ 74: 205–214. * Weinberg RA. . 1995 _Cell_ 81: 323–330.


* Whyte P, Williamson NM and Harlow E. . 1989 _Science_ 243: 934–937. * Wiman KG. . 1993 _Faseb J._ 7: 841–845. * Xiao ZX, Ginsberg D, Ewen M and Livingston DM. . 1996 _Proc. Natl. Acad.


Sci. USA_ 93: 4633–4637. * Zhang Y and Chellappan SP. . 1996 _Mol. Cell. Differ._ 4: 297–316. Download references ACKNOWLEDGEMENTS We thank Dr J Keith McClung for providing the prohibitin


cDNA and antibodies, as well as for helpful suggestions. This study was supported by a grant from the NCI (CA63136). SPC is a recipient of the Irma-Hirschl Trust Research Award. AUTHOR


INFORMATION AUTHORS AND AFFILIATIONS * Department of Pathology, College of Physicians and Surgeons, Columbia University, 630W 168th Street, New York, 10032, NY, USA Sheng Wang, Niharika Nath


 & Srikumar Chellappan * Department of Microbiology and Immunology, College of Physicians and Surgeons, Columbia University, 630W 168th Street, New York, 10032, NY, USA Matthew Adlam


Authors * Sheng Wang View author publications You can also search for this author inPubMed Google Scholar * Niharika Nath View author publications You can also search for this author


inPubMed Google Scholar * Matthew Adlam View author publications You can also search for this author inPubMed Google Scholar * Srikumar Chellappan View author publications You can also


search for this author inPubMed Google Scholar RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Wang, S., Nath, N., Adlam, M. _et al._ Prohibitin, a


potential tumor suppressor, interacts with RB and regulates E2F function. _Oncogene_ 18, 3501–3510 (1999). https://doi.org/10.1038/sj.onc.1202684 Download citation * Received: 01 September


1998 * Revised: 20 November 1998 * Accepted: 13 January 1999 * Published: 15 June 1999 * Issue Date: 10 June 1999 * DOI: https://doi.org/10.1038/sj.onc.1202684 SHARE THIS ARTICLE Anyone you


share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the


Springer Nature SharedIt content-sharing initiative KEYWORDS * Rb * E2F * cell cycle * transformation * tumor suppression